跳至主要内容
临床试验/NL-OMON52172
NL-OMON52172招募中4 期

The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome - Riluzole in 22q11.2 DS

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 46 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
46

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16 至 64(—)

入选标准

  • Confirmed diagnosis of 22q11.2 deletion syndrome established by FISH,
  • microarray or MLPA
  • 16 year or older of age and mentally competent (determined by an experienced
  • physician) to
  • decide about participation and give informed consent.
  • 16 years, incompetent to provide written informed consent. In these cases
  • consent will be
  • obtained from the legal representative of the subject.
  • Presence of psychotic and/or cognitive symptoms (defined as a score of >=4,
  • moderately ill, on the
  • Clinical Global Impression-Schizophrenia Scale (CGI-SCH)).

排除标准

  • Other chromosomal abnormalities.
  • Current substance abuse / dependence.
  • Use of psychotropic medication and / or first-generation antipsychotics or
  • clozapine, with the
  • exception of second-generation antipsychotics.
  • Contraindications for MRI.
  • Pre-existing liver function disorders and / or ALAT/ASAT > 3x ULN.
  • Contraindications for riluzole.
  • Pregnancy, or trying to get pregnant and breastfeeding.
  • In case of mentally incompetent patients, resistance to participation will be
  • an additional exclusion

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验

The glutamate/GABA balance as novel therapeutic... | 临床试验